Lower incidence of colorectal cancer and later age of disease onset in 27 families with pathogenic MSH6 germline mutations compared with families with MLH1 or MSH2 mutations: the German Hereditary Nonpolyposis Colorectal Cancer Consortium
- PMID: 15483016
- DOI: 10.1200/JCO.2004.02.033
Lower incidence of colorectal cancer and later age of disease onset in 27 families with pathogenic MSH6 germline mutations compared with families with MLH1 or MSH2 mutations: the German Hereditary Nonpolyposis Colorectal Cancer Consortium
Abstract
Purpose: The aim of the study was the analysis of the involvement and phenotypic manifestations of MSH6 germline mutations in families suspected of hereditary nonpolyposis colorectal cancer (HNPCC).
Patients and methods: Patients were preselected among 706 families by microsatellite instability, immunohistochemistry, and/or exclusion of MLH1 or MSH2 mutations and were subjected to MSH6 mutation analysis. Clinical and molecular data of MSH6 mutation families were compared with data from families with MLH1 and MSH2 mutations.
Results: We identified 27 families with 24 different pathogenic MSH6 germline mutations, representing 3.8% of the total of the families, and 14.7% of all families with DNA mismatch repair (MMR) gene mutations (n = 183). The median age of onset of colorectal cancer in putative mutation carriers was 10 years higher for MSH6 (54 years; 95% CI, 51 to 56) compared with MLH1 and MSH2 (44 years; 95% CI, 43 to 45; log-rank test, P = .0038). Relative to other malignant tumors, colorectal cancer was less frequent in MSH6 families compared with MLH1 and MSH2 families (Fisher's exact test, P < .001). In contrast, the frequency of non-HNPCC-associated tumors was increased (Fisher's exact test, P < .001).
Conclusion: Later age of disease onset and lower incidence of colorectal cancer may contribute to a lower proportion of identified MSH6 mutations in families suspected of HNPCC. However, in approximately half of these families, at least one patient developed colorectal or endometrial cancer in the fourth decade of life. Therefore, a surveillance program as stringent as that for families with MLH1 or MSH2 mutations is recommended.
Comment in
-
MSH6 mutations in hereditary nonpolyposis colon cancer: another slice of the pie.J Clin Oncol. 2004 Nov 15;22(22):4449-51. doi: 10.1200/JCO.2004.06.940. Epub 2004 Oct 13. J Clin Oncol. 2004. PMID: 15483012 No abstract available.
Similar articles
-
Immunohistochemistry and microsatellite instability testing for selecting MLH1, MSH2 and MSH6 mutation carriers in hereditary non-polyposis colorectal cancer.Oncol Rep. 2004 Sep;12(3):621-9. Oncol Rep. 2004. PMID: 15289847
-
Toward new strategies to select young endometrial cancer patients for mismatch repair gene mutation analysis.J Clin Oncol. 2003 Dec 1;21(23):4364-70. doi: 10.1200/JCO.2003.04.094. J Clin Oncol. 2003. PMID: 14645426
-
Extended microsatellite analysis in microsatellite stable, MSH2 and MLH1 mutation-negative HNPCC patients: genetic reclassification and correlation with clinical features.Digestion. 2004;69(3):166-76. doi: 10.1159/000078223. Epub 2004 Apr 28. Digestion. 2004. PMID: 15118395
-
Mutations associated with HNPCC predisposition -- Update of ICG-HNPCC/INSiGHT mutation database.Dis Markers. 2004;20(4-5):269-76. doi: 10.1155/2004/305058. Dis Markers. 2004. PMID: 15528792 Free PMC article. Review.
-
Mutations predisposing to hereditary nonpolyposis colorectal cancer.Adv Cancer Res. 1997;71:93-119. doi: 10.1016/s0065-230x(08)60097-4. Adv Cancer Res. 1997. PMID: 9111864 Review.
Cited by
-
Screening for Muir-Torre syndrome using mismatch repair protein immunohistochemistry of sebaceous neoplasms.J Genet Couns. 2013 Jun;22(3):393-405. doi: 10.1007/s10897-012-9552-4. Epub 2012 Dec 6. J Genet Couns. 2013. PMID: 23212176
-
[Sebaceous gland tumor with a rare gene mutation within a tumor syndrome: Muir-Torre syndrome].Ophthalmologe. 2014 Apr;111(4):369-72. doi: 10.1007/s00347-013-2879-x. Ophthalmologe. 2014. PMID: 23774967 German.
-
Thyroid cancer in a patient with a germline MSH2 mutation. Case report and review of the Lynch syndrome expanding tumour spectrum.Hered Cancer Clin Pract. 2008 Feb 15;6(1):15-21. doi: 10.1186/1897-4287-6-1-15. Hered Cancer Clin Pract. 2008. PMID: 19706203 Free PMC article.
-
A review on the molecular diagnostics of Lynch syndrome: a central role for the pathology laboratory.J Cell Mol Med. 2010 Jan;14(1-2):181-97. doi: 10.1111/j.1582-4934.2009.00977.x. Epub 2009 Nov 19. J Cell Mol Med. 2010. PMID: 19929944 Free PMC article. Review.
-
Consequences of universal MSI/IHC in screening ENDOMETRIAL cancer patients for Lynch syndrome.Gynecol Oncol. 2014 Aug;134(2):319-25. doi: 10.1016/j.ygyno.2014.06.009. Epub 2014 Jun 14. Gynecol Oncol. 2014. PMID: 24933100 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Molecular Biology Databases
Miscellaneous
